Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease

Active, not recruitingOBSERVATIONAL

Enrollment

1,118

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Coronary Arterial Disease (CAD)

Trial Locations (1)

Seoul National University Bundang Hospital, Seongnam

All Listed Sponsors

lead

Genoss Co., Ltd.

INDUSTRY

NCT06841510 - Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease | Biotech Hunter | Biotech Hunter